Company: BOLT
Filing Date: 2025-01-03
Form Type: 8-K
Source: 0000950170-25-001159
Chunk: 0

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-01-03
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on July 2, 2024, the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq”) notified Bolt Biotherapeutics, Inc. (the “ Company”) that, based on the previous 30 consecutive business days, its common stock no longer met the minimum $1.00 bid price per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Requirement”). Therefore, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until December 30, 2024, to regain compliance. As the Company did not regain compliance with the Minimum Bid Requirement by December 30, 2024, the Company applied to transfer the listing of its common stock to The Nasdaq Capital Market, as allowed under Nasdaq Listing Rule 5810(c)(3)(A), in order to qualify for an additional 180 calendar days to regain compliance.

On January 2, 2025, the Company received written notice from Nasdaq notifying the Company that its application to transfer the listing of its common stock to The Nasdaq Capital Market was approved. The approval is based upon the Company meeting the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the Minimum Bid Requirement), the Company’s written notice of its intention to cure the deficiency by effecting a reverse stock split, if necessary, its agreement to the conditions outlined in the Nasdaq listing agreement, and additional supporting information provided in its application.

The Company’s common stock will be transferred to The Nasdaq Capital Market at the opening of business on January 6, 2025, and the Company will be granted an additional 180 calendar days, or until June 30, 2025, to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time during this additional 180-day compliance period. If the Company regains compliance with the Minimum Bid Requirement, Nasdaq will provide the Company with written confirmation of compliance and will close the matter.

If the Company does not regain compliance with the Minimum Bid Requirement by June 30